Banque Cantonale Vaudoise Has $8.91 Million Holdings in Gilead Sciences, Inc. $GILD

Banque Cantonale Vaudoise trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 16.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 80,278 shares of the biopharmaceutical company’s stock after selling 16,310 shares during the quarter. Banque Cantonale Vaudoise’s holdings in Gilead Sciences were worth $8,910,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Corundum Trust Company INC bought a new position in shares of Gilead Sciences during the third quarter worth approximately $26,000. Howard Hughes Medical Institute bought a new stake in shares of Gilead Sciences in the second quarter valued at approximately $30,000. MTM Investment Management LLC boosted its stake in shares of Gilead Sciences by 176.0% in the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 176 shares during the period. Kilter Group LLC acquired a new stake in Gilead Sciences during the second quarter worth approximately $33,000. Finally, Millstone Evans Group LLC grew its position in Gilead Sciences by 58.7% during the third quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 118 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Morgan Stanley lifted their price objective on Gilead Sciences from $150.00 to $171.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Wall Street Zen lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Needham & Company LLC restated a “buy” rating and issued a $170.00 price target on shares of Gilead Sciences in a research report on Monday, February 23rd. UBS Group boosted their price target on Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Gilead Sciences from $150.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Twenty-three analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $156.72.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $154.43, for a total value of $463,290.00. Following the sale, the chief financial officer directly owned 167,779 shares in the company, valued at approximately $25,910,110.97. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the sale, the insider directly owned 120,288 shares in the company, valued at $18,577,278.72. This trade represents a 18.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 309,280 shares of company stock worth $43,935,470 over the last three months. 0.27% of the stock is owned by insiders.

Gilead Sciences Trading Up 1.9%

Shares of GILD stock opened at $146.63 on Tuesday. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $157.29. The stock’s fifty day moving average price is $138.73 and its two-hundred day moving average price is $126.06. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. The company has a market cap of $182.03 billion, a PE ratio of 21.66, a P/E/G ratio of 1.89 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. During the same quarter in the previous year, the firm earned $1.90 EPS. Gilead Sciences’s revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a yield of 2.2%. Gilead Sciences’s payout ratio is presently 46.68%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.